Published in Biotech Business Week, July 11th, 2005
Graham will be responsible for directing all clinical development and medical affairs activities and will play a vital role in supporting Fuzeon (enfuvirtide) in the marketplace, as well as providing stewardship of pipeline development programs. Lynn Smiley, MD, formerly senior vice president of clinical research, will assume the role of senior vice president of regulatory affairs, compliance, and drug safety.
Graham previously was chief medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.